(Reuters) - Genetic testing specialist Qiagen
But while Qiagen could boost profits by focusing on products identifying the coronavirus it will continue to bet on growth in its molecular diagnostics business, rather than uncertain one-off gains, CEO Thierry Bernard told a results conference call.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
